scispace - formally typeset
W

Weiping Ma

Researcher at Icahn School of Medicine at Mount Sinai

Publications -  31
Citations -  2616

Weiping Ma is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Proteogenomics & Cancer. The author has an hindex of 13, co-authored 29 publications receiving 1094 citations. Previous affiliations of Weiping Ma include Fudan University.

Papers
More filters
Journal ArticleDOI

Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma

TL;DR: The first proteogenomic characterization of hepatitis B virus-related hepatocellular carcinoma using paired tumor and adjacent liver tissues from 159 patients provides a valuable resource that significantly expands the knowledge of HBV-related HCC and may eventually benefit clinical practice.
Journal ArticleDOI

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

David J. Clark, +224 more
- 31 Oct 2019 - 
TL;DR: A large-scale proteogenomic analysis of ccRCC is reported to discern the functional impact of genomic alterations and provides evidence for rational treatment selection stemming fromccRCC pathobiology.
Journal ArticleDOI

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Michael A. Gillette, +189 more
- 09 Jul 2020 - 
TL;DR: Comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK.
Journal ArticleDOI

Proteogenomic Characterization of Endometrial Carcinoma.

Yongchao Dou, +219 more
- 20 Feb 2020 - 
TL;DR: A comprehensive proteogenomic characterization of endometrial carcinomas revealed possible new consequences of perturbations to the p53 and Wnt/β-catenin pathways, identified a potential role for circRNAs in the epithelial-mesenchymal transition, and provided new information about proteomic markers of clinical and genomic tumor subgroups, including relationships to known druggable pathways.